Medable Sets Stage for Broad Decentralized Clinical Trial Adoption in 2021

Shares Business Impact, Insights and Predictions for Patient-Centered Drug Development at JPM 2021

PALO ALTO, Calif.--(BUSINESS WIRE)-- Medable Inc, the leading cloud platform for patient-centered drug development, experienced record growth in 2020 as the COVID-19 pandemic drove demand for remote clinical trial technologies. By minimizing the need for in-person site visits, Medable customers have achieved unprecedented results – including 3X faster enrollment and over 90 percent retention rates.

Medable onboarded more than 50 new clients in 2020, as pharmaceutical, biotech, and clinical research organizations used Medable’s software to enable patients to participate in trials remotely — reducing their dependence on physical sites due to quarantines and social distancing. Decentralized trial adoption grew Medable revenues by more than 400 percent in 2020. Additionally, Medable launched five new products to support patient-centered research, and secured $118 million in total funding to accelerate digital and decentralized clinical trial adoption.

“COVID-19 accelerated patient-centered research by five years,” said Dr. Michelle Longmire, CEO and co-founder of Medable. “2021 will be marked by the democratization of access to research. Leveraging Medable, partners can provide remote access to new investigational medicines to patients worldwide. We are driving radical transformation in clinical trials through patient-centered technologies that remove traditional bottlenecks and transform key processes. In 2021, Medable will continue to drive the emergence of a global ecosystem that truly enables research anytime, anywhere and for every person.”

Digital and mobile technologies played a pivotal role for clinical trials in 2020, enabling the continuation of in-flight research efforts via remote care while also accelerating development of vaccines and therapeutics for COVID-19. Building on that experience, Medable executives will share lessons learned from 2020 and predictions for 2021, via five sessions at this week’s Fierce JPM Week 2021 and Digital Medicine & MedTech Showcase events:

Rerouting: How Real-Time Patient Data Will Drive the Future of Healthcare
Moderator: Dr. Michelle Longmire, CEO, Medable
Panelists: Andy Coravos, CEO, Elektra Labs | Maria Fotiu, Executive VP of Decentralized Solutions, Syneos Health | Thomas Switzer, Digital Health Scientist, Genentech | Dr. Priyanka Agarwal, Director and Head of Digital Health, Myokardia

Patient-Driven Therapeutics: Charting the Future of Healthcare
Presented by: Dr. Michelle Longmire, CEO, Medable
Interviewed by: Sari Kaganoff, General Manager, Rock Health

The Digitalization of Clinical Trials
Moderator: Maria Fotiu, Executive VP of Decentralized Solutions, Syneos Health
Panelists: Dr. Michelle Longmire, CEO, Medable | Cathy Gao, VP, Sapphire Ventures | Juliet Moritz, COO, Illingworth Research

Hindsight is 2020: Lessons Learned from DCTs and 2021 Predictions
Presented by: Allison Holland, Head, Decentralized Clinical Trials, Medable | Craig Lipset, Industry Founder and Advisor

User Experience: From the Patient, Site and Sponsor View
Presented by: Rasmus Hogreffe, VP of DCT Innovation, Medable
Interviewed by: Karina Marocco, EBD Group

Please click here for more information about Medable’s presence at JPM 2021, or to schedule a meeting with Medable’s executives. For ongoing insight about decentralized trial adoption, advice and best practices, and patient-centered research, follow Medable via our blog, LinkedIn, Twitter and Facebook channels.

About Medable

Medable is on a mission to get effective therapies to patients faster by transforming clinical drug development with disruptive technologies. The company’s digital platform streamlines design, recruitment, retention and data quality for decentralized trials, replacing siloed systems with integrated digital tools, data and interfaces to accelerate trial execution. Medable connects patients, sites and clinical trial teams to improve patient access, experience, and outcomes. Medable is a privately held, venture-backed company headquartered in Palo Alto, California.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005436/en/